Drugs in MeSH Category Sodium Channel Blockers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212930-002	May 18, 2021		DISCN	No	No
Ajanta Pharma Ltd	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	210054-002	May 28, 2019	AB	RX	No	No
Mylan Institutional	AMIODARONE HYDROCHLORIDE	amiodarone hydrochloride	INJECTABLE;INJECTION	076217-001	Oct 15, 2002	AP	RX	No	Yes
Teva	AMIODARONE HYDROCHLORIDE	amiodarone hydrochloride	TABLET;ORAL	074895-001	Apr 16, 1999		DISCN	No	No
Cipla	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	211291-001	May 28, 2019		DISCN	No	No
Arthur Grp	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212781-002	Mar 23, 2020	AB	RX	No	No
Amneal	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	207690-001	Mar 11, 2021		DISCN	No	No

Sodium Channel Blockers (MeSH): Market Dynamics and Patent Landscape for Key Drugs in US and EU

Last updated: May 25, 2026

Executive summary: Sodium channel blockers span multiple therapeutic segments including antiarrhythmics (Class I/III adjuncts), epilepsy/neuropathic pain (voltage-gated Na+ channel inhibitors), and migraine prophylaxis. The patent and exclusivity picture is dominated by (1) incremental formulation and method-of-use patents layered on top of core active-ingredient filings, (2) US Orange Book expiry risk tied to earliest non-expired listed patents and granted pediatric exclusivity where applicable, and (3) biosimilar risk being largely irrelevant to small molecules, with competition instead coming from generics, authorized generics, and carve-outs for abuse-deterrent or extended-release systems. Net effect: near-term market entry risk concentrates in older small-molecule sodium channel blockers where the first patent barrier is the last listed formulation or method-of-use claim, while newer branded agents retain leverage via layered secondary patents and life-cycle extensions.

---

What sodium channel blockers are in NLM MeSH class and how do their patent estates differ by mechanism?

NLM MeSH “Sodium Channel Blockers” is a pharmacologic class covering small molecules that inhibit voltage-gated sodium channels (Nav), used across seizure disorders, pain syndromes, and cardiac rhythm management. Patent estates typically stratify by whether the marketed product relies on:

• Core active-ingredient novelty (early composition-of-matter patents).
• Therapeutic use novelty (method-of-use patents for indication-specific claims).
• Drug-product novelty (extended-release, controlled-release, formulation, and abuse-deterrent technologies).
• Dosing regimen novelty (intervals, titration schedules, patient subgroups).

Common sodium channel blocker actives appearing across major indications

Because MeSH contains multiple drug and class descendants, commercial patent analysis usually focuses on actives that have established FDA approvals with listed US patents. Core examples routinely evaluated in market and IP work include:

• Carbamazepine (anti-seizure)
• Oxcarbazepine (anti-seizure)
• Lamotrigine (sodium channel modulation; overlaps broader mechanism classification)
• Phenytoin (anti-seizure)
• Topiramate (Na+ channel modulation alongside other mechanisms)
• Lidocaine (local anesthetic)
• Flecainide, propafenone, mexiletine (antiarrhythmics)
• Riluzole (ALS; includes sodium channel-related activity)
• Zonisamide (anti-seizure; includes Na+ channel effects)

How the patent estate structure changes by product design

• Immediate-release (IR) generics face lower product-specific barriers once composition-of-matter patents expire.
• Extended-release (ER) and sustained-release (SR) products often carry formulation or release-profile patents that can remain listed after the core API patents expire.
• Abuse-deterrent technologies, where present, add a durable layer of patent coverage at the product level (technology claims for dosage-form behavior).

---

Which sodium channel blocker drugs have the strongest US patent estate today?

A “strongest estate” in practice means multiple granted, Orange Book-listed US patents with staggered expirations, including at least one product-formulation or method-of-use barrier that remains enforceable beyond the API expiry.

Featured-snippet answer

Sodium channel blockers with the strongest near-to-mid-term US exclusivity typically combine: (1) newer NDA/BLA approvals or new molecular entities, (2) ER or specialized delivery formulations, and (3) multiple Orange Book “listed” patents spanning composition, formulation, and method-of-use.

Estate strength indicators used in deal and litigation screens

• Number of Orange Book listed patents per product (more is not always stronger, but it increases blocking points).
• Earliest expiration among listed patents by type:
  • Composition-of-matter
  • Formulation/composition (including dosage form)
  • Method-of-use
• Whether any listed patent is tied to a post-approval change (line extension) rather than the original approval.
• Existence of follow-on FDA approvals (IR-to-ER switches) with separate listing sets.

---

When do sodium channel blocker products lose exclusivity in the US (Orange Book timing)?

Exclusivity in the US for sodium channel blockers generally comes from two layers:

1. Patent exclusivity via Orange Book-listed listed patents and the earliest effective “barrier” for generic entry.
2. Statutory exclusivity (e.g., 5-year new chemical entity (NCE), 3-year new clinical investigation (NCE-adjacent), pediatric exclusivity added to patent term in limited cases).

Featured-snippet answer

For most sodium channel blockers, exclusivity loss in practice tracks the last-to-expire listed patent that still blocks FDA approval under the Paragraph IV or non-PIV certification strategy, not the date of first approval.

Practical timing map used by business teams

• T0 (launch): initial FDA approval date.
• T1 (first listed patent expiry): earliest listed patent expiration.
• T2 (last listed patent expiry): last listed patent expiration that blocks full generic carve-out-free entry.
• T3 (Exclusivity window): statutory exclusivity often runs alongside patents and can prevent generic approvals even if some patents expire, depending on certifications and patent status.

---

What patents protect sodium channel blockers from generic entry (composition, formulation, method-of-use)?

Typical patent categories that show up for sodium channel blocker lifecycle

1. Composition-of-matter (API)
   Covers the active ingredient and sometimes salts or stereoisomers.
2. Pharmaceutical composition
   Covers specific excipient systems, dosage form characteristics, and stability.
3. Controlled release formulation
   Covers release curves, matrix geometry, coating characteristics, or polymer blends.
4. Method-of-use
   Covers dosing regimens, therapeutic indications, or titration strategies.
5. Use-dependent combination
   Less common for sodium channel blocker MeSH members, but still appears where combination therapy is claimed.

Featured-snippet answer

Generic entry risk is highest against the final Orange Book-listed formulation or method-of-use patent that still matches the generic label (same dosage form, same release profile, same population/indication).

---

How many Orange Book listed patents cover major sodium channel blocker products and how does that affect Paragraph IV risk?

Decision-grade statement

Products with a large number of Orange Book patents often face frequent Paragraph IV certifications, but the real-world determinant is whether those patents are:

• granted and active (not expired/invalidated),
• still asserted or plausibly assertable,
• tied to claims that read onto the generic product and label.

Litigation leverage profile

• Early-expiring patents often invite Paragraph IV challenges with settlement-driven “at-risk” launching once the blocking patent resolves.
• Late-expiring formulation or method patents drive longer settlements or “carve-out-only” launches that avoid infringing claims.

---

What Paragraph IV challenges have been filed against sodium channel blocker drugs?

Featured-snippet answer

Paragraph IV challenges in sodium channel blockers are typically concentrated on products whose core exclusivity windows have narrowed, especially when ER formulation or indication-specific method patents are the remaining barrier.

Litigation pattern

Common settlement outcomes include:

• Staggered launch dates aligned to partial patent wins.
• Carve-out labels for specific indications or dosing strengths.
• Design-around formulations (different excipient systems or release kinetics) where formulation claims are broad enough to cover generic product design.

Note: Specific case-by-case Paragraph IV filings must be pulled from USPTO/PACER dockets and FDA Orange Book listings by product and strength. Without a drug-specific scope, a reliable enumeration cannot be provided.

---

How strong is the patent estate for sodium channel blockers versus generics (invalidation, design-around, and settlement behavior)?

Strength drivers

• Claim breadth: formulation patents that claim release profile ranges typically face more design-around attempts than those that tie to specific compositions or process steps.
• Process claims (rare compared with composition/formulation): may be harder to design around and can support injunction leverage.
• Method-of-use: strong when claims require physician-directed or patient criteria not easily carved out.

Weakness drivers

• Overlapping prior art for incremental modifications.
• Conformance limits: if generic products cannot replicate the claimed formulation parameters, courts may narrow infringement.
• Settlement probability: as patent term shortens, settlement drives “license then entry” more frequently than protracted trials.

---

How does sodium channel blocker patent coverage vary across the EU (SPCs, patent term extensions, national designations)?

EU exclusivity architecture differs

EU protection frequently uses a combination of:

• Basic patent (composition or formulation)
• Supplementary Protection Certificate (SPC) extending patent protection for authorized medicinal products
• Regulatory exclusivity provisions and marketing authorization data protection periods

Featured-snippet answer

EU “last barrier” timing is often determined by the SPC expiry date, which can diverge from US Orange Book dates. For life-cycle extensions (new strengths/indications), SPC strategy can materially change entry timing by geography.

---

What formulations of sodium channel blockers are protected and how do that change generic risk?

Featured-snippet answer

Formulation protection is the primary reason many sodium channel blocker generics launch later than expected based only on API patent expiry. ER/SR products are the highest-impact formulation-protected segment.

Design-around risk categories

• Release-rate claims: hardest if claims cover a continuous range and are supported by data.
• Dosage-form architecture: matrix/coating-specific claims can force process changes.
• Bioequivalence to label: even if the API is the same, generic must match release behavior enough to meet BE/PK targets.

---

Which companies are positioned for market share gains as sodium channel blocker exclusivity ends?

Market entry in sodium channel blockers typically involves:

• Global and regional generic manufacturers with ANDA programs and ANDA-to-launch execution.
• Authorized generics through brand-company settlements.
• “Design-around” entrants for formulation-protected ER products where challenging patents leads to noninfringing product designs.

Competitive dynamic

• When the remaining barrier is formulation/method, entrants with expertise in dose-form manufacturing and BE/PK strategy tend to be favored.
• When the remaining barrier is early-identified (composition or method with broad claim scope), entrants often pursue settlement-driven entry instead of full litigation.

Note: a precise company-by-company ranking requires product-level Orange Book and litigation mapping.

---

How do settlement agreements and “at-risk” launching affect sodium channel blocker competition timelines?

Typical settlement timeline mechanics

• Settlement often includes:
  • entry date (future),
  • carve-outs or agreed labels,
  • non-attempt or covenant terms for additional patents.
• When formulation patents are involved, design-around may be permitted with specific label limitations.

Revenue exposure linkage

For brand owners, the economic impact depends on whether generic entry is:

• Generic-to-generic substitution (no carve-out) or
• Partial substitution (only some strengths/indications).

---

What FDA status matters for sodium channel blocker patents (NDA vs ANDA vs 505(b)(2))?

Featured-snippet answer

Patent linkage and generic entry routes vary by pathway. Many sodium channel blockers are challenged through ANDAs (Paragraph IV) when the product is identical/BE. Reformulated versions or new salts/combos often use 505(b)(2), which can change how patents are listed and how certifications apply.

Regulatory status factors

• Listed patents in Orange Book for each strength/dosage form.
• Whether the proposed generic seeks approval for the same label indications.
• Whether any existing 505(b)(2) reformulation has its own patent listing set.

---

What generic entry risks exist for sodium channel blocker ER products?

Risk drivers

• Formulation patents that map to ER technology.
• Method-of-use patents tied to dosing patterns or patient groups.
• BE/PK sensitivity for ER products: small formulation differences can break BE or increase label change needs.

Featured-snippet answer

ER sodium channel blocker products face the highest generic entry risk where remaining patents are product-formulation specific rather than composition-of-matter.

---

How does sodium channel blocker patent risk differ by therapeutic area (epilepsy vs neuropathic pain vs antiarrhythmics)?

Epilepsy / neuropathic pain

• Method-of-use patents can be indication-specific (treatment of specific seizure types or pain conditions).
• Patient subgroups and titration protocols can create label carve-out constraints.

Antiarrhythmics

• Commercial competition is tightly label-driven, especially for class-specific cardiac indications.
• Product tolerability and monitoring-driven dosing regimens can support method claims in some portfolios.

---

Key Takeaways

• Sodium channel blocker exclusivity is driven less by the earliest API patent and more by Orange Book-listed formulation and method-of-use patents, especially for ER/SR products.
• US generic entry risk is highest when the last blocking patents are dosage-form or indication-specific and map tightly to the generic’s proposed label.
• EU entry timing often diverges from US due to SPC expiries, creating geography-specific risk and licensing leverage.
• Without product-level Orange Book and litigation mapping, a reliable “which patents expire when” or “which companies challenged what” ranking cannot be stated for the MeSH class as a whole.

---

FAQs

Which sodium channel blocker drugs have Orange Book patents that extend beyond the API patent term?

ER/SR and indication-specific method patents commonly extend the effective barrier beyond API expiry, but drug-level verification is required to identify which exact products have the later barriers.

Do sodium channel blockers have biosimilar competition risk?

No. Biosimilar risk is not applicable to small-molecule sodium channel blockers; the competitive threat is generics, authorized generics, and reformulated line extensions.

What is the most common reason a sodium channel blocker generic launch is delayed?

The most frequent cause is a remaining Orange Book-listed formulation or method-of-use patent that still covers the generic dosage form and label.

Can generic manufacturers design around formulation patents for ER sodium channel blockers?

Yes, when formulation claims are not tied to narrowly defined composition/process constraints. When claims cover broad release profiles or core ER architecture, design-around risk increases.

How do EU SPC expiries change sodium channel blocker entry compared with the US?

EU SPCs can extend protection past the period implied by US API patent expiry, shifting launch risk by geography and often supporting different settlement timelines.

---

References (APA)

1. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
2. National Library of Medicine. MeSH (Medical Subject Headings): Sodium Channel Blockers. https://meshb.nlm.nih.gov/
3. U.S. FDA. Drug Approval Reports / Drug Trials Snapshots (by product pathway and application details). https://www.fda.gov/drugs/drug-approvals-and-databases/